TTP's new spin-out Cellular Highways to commercialize advanced cell-sorting technology

TTP plc (TTP), a leading independent technology and product development company, has announced today the formation of Cellular Highways Ltd.

The new spin-out has been founded to commercialize TTP’s proprietary Vortex-Actuated Cell Sorting (VACS) technology, and fast-track development of a first commercial product, Highway 1.

TTP has invested £1.7m ($2.2m) in the spin-out, in addition to over £2m development funding to date. Highway 1 will be unveiled at CYTO, the 34th Congress of the International Society for Advancement of Cytometry, in Vancouver, 22-26 June 2019.

The VACS technology has the potential to enable new cell therapies, liquid biopsy diagnostics, and high-throughput drug discovery applications. It is the first cell sorting technology with the demonstrated core performance to translate research to the clinic, enabling high-throughput cell sorting that is sterile and free of cross-contamination, and scalable to therapeutically-relevant batches of cells.

VACS provides an enclosed, sterile cell sorting chip, where cells can be typed according to molecular markers, and sorted into separate outputs. Importantly, the technology is multiplexable, enabling scaling up to large batches of cells (upwards of around a billion) at high speed, to support development of cell therapies and diagnostics.

A team at TTP, led by Dr Salman Samson Rogers, has been developing the VACS technology over the past two years. To exploit the potential of the VACS platform, TTP has launched Cellular Highways to develop a new generation of automated high-throughput cell sorting instruments for research, diagnostic and therapeutic applications.

Dr Rogers has also been appointed CEO of Cellular Highways. Highway 1, Cellular Highways’ first commercial product, has been designed to provide “an aseptic cell sorter for every lab”. Input and output fluids are entirely contained in sterile sort microfluidic cartridges, which house the inertial sorter chip, to eliminate risks associated with biohazardous aerosols, and cross-contamination.

Cellular Highways will be based at TTP’s Melbourn Science Park headquarters.

Our mission is to make better cell sorting accessible to every laboratory, and to enable therapeutic and diagnostic cell sorting applications that are ill-served by incumbent products. Powered by VACS technology, our instruments will reduce the cost and complexity of cell sorting and will be easy to operate. We are interested in hearing from beta testers, research partners, new colleagues and anyone with an interest in better cell sorting.”

Dr Salman Samson Rogers, CEO at Cellular Highways

Investing in new technology and product development is at the heart of what we do at TTP. The launch of Cellular Highways is a great example of what happens when technically brilliant people come together, working across disciplines in a collaborative and creative environment. I want to thank the Cellular Highways team for all their hard work so far and I am looking forward to the launch of Highways 1.”

Matthew Carr, Head of Life Sciences at TTP and Chairman of Cellular Highways


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    TTP plc. (2019, June 24). TTP's new spin-out Cellular Highways to commercialize advanced cell-sorting technology. News-Medical. Retrieved on June 23, 2024 from

  • MLA

    TTP plc. "TTP's new spin-out Cellular Highways to commercialize advanced cell-sorting technology". News-Medical. 23 June 2024. <>.

  • Chicago

    TTP plc. "TTP's new spin-out Cellular Highways to commercialize advanced cell-sorting technology". News-Medical. (accessed June 23, 2024).

  • Harvard

    TTP plc. 2019. TTP's new spin-out Cellular Highways to commercialize advanced cell-sorting technology. News-Medical, viewed 23 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
TTP partners with Quotient to transform transfusion diagnostics and beyond